Behavior, Biology, and Chemistry:
Translational Research in Addiction

ARTT Center of Excellence

2017 BBC Symposium

The opioid epidemic: history, formulations, regulations, and emergencies

Symposium Speakers

Chairs: Andrew Coop, PhD and James H Woods, PhD

Lewis S. Nelson, MD

Professor and Chair Department of Emergency Medicine
New Jersey Poison Information & Education System
Rutgers New Jersey Medical School

From opiophobia to abuse deterrent formulations: The making of an opioid epidemic.

Lewis Nelson, MD is an emergency physician and medical toxicologist who has worked closely with patients, families, clinicians, governmental agencies, and others to understand and control the opioid epidemic.

Mansoor Khan, PhD

Professor and Vice Dean of College Station Campus
Texas A&M Irma Lerma Rangel College of Pharmacy
Texas A&M Health Science Center

Abuse Deterrent Formulations: Design Strategies and Evaluation

Information coming soon!

Silvia N Calderon, PhD

US Food & Drug Administration

Prescription Opioids: Abuse Potential, Scheduling and the Current Opioid Epidemic

Dr. Calderon is a Senior Scientist in the Center for Drug Evaluation and Research (CDER), Controlled Substance Staff (CSS). She received her Ph.D. in Medicinal Chemistry from the University of Buenos Aires, Argentina, and her training and expertise are concentrated in the fields of medicinal chemistry and pharmacology of drugs of abuse. Currently, she advises pharmacologists on the abuse liability assessment of new drug products and formulations, and provides guidance regarding policy and review issues.

Andrew Coop, PhD

Department of Pharmaceutical Sciences
University of Maryland School of Pharmacy

Beyond formulations: Solving the opioid epidemic with new chemical entities

Dr. Coop received his PhD in from the University of Bristol in the area of chemistry of drugs of abuse, followed by a Fogerty post-doctoral fellowship at the National Institutes of Health. He has been a faculty member in the Department of Pharmaceutical Sciences since 1999, serving as chair of the department from 2007-2015. His NIDA-funded research area focuses on the design and synthesis of new opioid analgesics with reduced tolerance.

Funding for this conference is made possible [in part] by R13 DA029347 from The National Institute on Drug Abuse (NIDA). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.